INTERVIEW: The Biosimilar Brain - Celltrion’s Dr. Stanley Hong
This article was originally published in PharmAsia News
South Korean firm Celltrion Healthcare is a pioneer in the biosimilar space, having launched the world's first monoclonal antibody biosimilar, Remsima (infliximab), which was rolled out across Europe earlier this year and is currently under review by the US FDA. Celltrion CEO talks about the impact the product will have and how will the broader biosimilar sector will develop.
Register for our free email digests: